Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respiratory

Set Alert for Respiratory

Pulmocide Grows Cash Pile For Promising Antifungal

The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.

Financing Respiratory

C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug

The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships. 

Deals Companies

GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.

Commercial Companies

Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023

Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.

Sales & Earnings Commercial

AstraZeneca’s Fasenra Future Weakened By Pivotal Eosinophilic Esophagitis Trial Flop

The major’s monoclonal antibody drug missed one of two primary endpoints in a late-stage eosinophilic esophagitis trial in the second setback this year to plans for label expansion beyond the asthma maintenance setting.

Clinical Trials Respiratory

Verona Boosts Funds And Becomes Potential Takeover Target

The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.

Business Strategies Clinical Trials

Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma

With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.

Approvals Respiratory

Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test

Moderna needs to develop new mRNA-based therapies beyond COVID-19, and flu and RSV will be the big readouts in 2023.

Companies Coronavirus COVID-19

Verona Transformed After Phase III Victory For COPD Therapy

The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.

Clinical Trials Respiratory

AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost

The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.

Companies Approvals

GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial

GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.

Clinical Trials Commercial

Enanta’s Path Forward Uncertain After RSV Failure

The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.

Clinical Trials Respiratory
See All
UsernamePublicRestriction

Register